52-Week Highs and Lows, March 19, 2026

Ugly session across small cap biotech. 13 new 52-week lows vs only 2 new highs. The ratio tells the whole story. Broad market pressure is dragging names lower regardless of fundamentals. This is the kind of tape where your watchlist gets built.

New 52-Week Highs

TYRA $38.53. Bucking the entire market. When a biotech is printing new highs while everything else bleeds, pay attention. Pipeline momentum is real here.

ELVN $31.76. Another name showing serious relative strength in a weak tape. Strength into weakness is one of the most reliable signals in this space.

New 52-Week Lows

MNKD $2.48. This one hurts to see down here. Thinkorswim has been a commercial story with real revenue. At this level the valuation is getting interesting for anyone with a longer time horizon.

SLNO $32.15. Still a decent market cap even at a 52-week low. Worth watching whether this is broad market noise or something company-specific.

HUMA $0.81. Don't let the price scare you. They just completed a raise, have been over $1 recently and will be again. Milestone payments kick in upon approval. This is dilution pressure from the raise, not a fundamental collapse.

RVPH $1.82. Has crashed all the way back to pre-reverse split levels. That's a brutal round trip. Worth watching whether this finds a floor or if there's more unwinding to come.

ORGO $2.30 DRIP $4.32 MAIN $46.07 AGMB $12.61 NSRX $2.40 SER $1.22 BCYC $4.47 DARE $1.27

The takeaway. Days like this are why you keep cash. Most of these names are getting sold because the market is selling everything, not because their stories changed. Build your list, scale in slowly, and remember that 52-week lows in biotech are where M&A premiums get built. Acquirers love discount shopping.